Evaluation of Safety and Dosing of a Vitamin C Bundle for Sepsis Treatment in Africa

Last updated: September 6, 2021
Sponsor: Liverpool School of Tropical Medicine
Overall Status: Active - Recruiting

Phase

2

Condition

Sepsis And Septicemia

Low Blood Pressure (Hypotension)

Hiv

Treatment

N/A

Clinical Study ID

NCT04999137
19-094
  • Ages > 18
  • All Genders

Study Summary

Open-label phase 2a Randomized Controlled Trial (RCT) assessing the pharmacokinetics of two different doses of intravenous vitamin C given alongside vitamin B1 in adult medical patients with sepsis and hypotension.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Adult (≥18 years old) patients presenting to the emergency department of KirudduNational Referral Hospital (KNRH) with:
  • suspected infection [(any of): temperature >38 degrees Celsius or <36 degreesCelsius or (in the past seven days) fevers, rigors, night sweats or antibioticuse]; AND
  • systolic blood pressure (SBP) <90 mmHg
  1. Evidence of a personally signed and dated informed consent document indicating thatthe subject (or a legal representative) has been informed of all pertinent aspects ofthe study.
  2. Subjects who are willing and able to comply with scheduled visits, treatment plan,laboratory tests and other study procedures.

Exclusion

Exclusion Criteria:

  1. Pregnant or known active breast feeding
  2. Non-severe, localized, uncomplicated infection (e.g., cellulitis with only localsymptoms) which is apparent on clinical examination
  3. Severe bleeding or hemorrhagic shock
  4. Hypotension likely secondary to a cause other than sepsis or sepsis-induced cardiacinsufficiency
  5. Detainee or prisoner
  6. Admission to a surgical or obstetric/gynecological ward
  7. Emergency surgery required
  8. Previously recruited to the REVISTA-DOSE study
  9. History of end stage renal disease requiring dialysis
  10. Current symptomatic renal stones or or a previous diagnosis of primary hyperoxaluriaor oxalate nephropathy
  11. History of allergic reactions to vitamin C or vitamin B1
  12. Use of vitamin C at a dose greater than 1 g (oral or intravenous) within 24 hours ofscreening
  13. Chronic disease/illness that, in the opinion of the site investigator, has a lifespanof less than 30 days unrelated to current sepsis diagnosis (e.g., advanced malignancyor neurodegenerative disease).
  14. Previous or current enrolment in a trial in which co-enrolment is not allowed

Study Design

Total Participants: 60
Study Start date:
September 01, 2021
Estimated Completion Date:
December 29, 2021

Study Description

Sepsis is a life-threatening infection which, due to a dysregulated host response to infection, is responsible for more than 11 million deaths annually, a large percentage of which occur in sub-Saharan Africa (sSA). Emerging research shows promising benefits in treating sepsis patients with "metabolic resuscitation" using combinations of hydrocortisone, intravenous (IV) ascorbic acid (vitamin C) and IV thiamine (vitamin B1), alone or in combination. Studies are currently underway in the USA, Europe, Asia, and South America to understand whether combinations of these medicines or the medicines individually can improve outcomes for patients with sepsis. Although none of these studies are being conducted in sSA, the medicines comprising these metabolic 'bundles' are inexpensive, readily available and relatively safe to administer. It is critical that similar studies are conducted in sSA to evaluate whether or not these inexpensive medicines (or a combination of them) are efficacious for improved survival among patients with sepsis. If these studies prove that these medicines can improve survival from sepsis, there is a large potential to save many lives. Through the Preparation for Randomised Evaluation of a VItamin C bundle for Sepsis Treatment in Africa (REVISTA-Prep) studies, the investigators intend to conduct preliminary research in Uganda to help define parameters for a future RCT aimed at identifying the optimal vitamin C and vitamin B1 combination for improving survival from sepsis among adults in sSA, where resources are constrained, intensive care units are rare and issues like poverty, malnutrition and HIV are common. The study described in this protocol (i.e., REVISTA-DOSE) aims to establish the optimal vitamin C dosing strategy for the future REVISTA-RCT (assessing the efficacy of variations of a treatment bundle comprising vitamin C/B1 and/or hydrocortisone for reducing mortality among adult patients with sepsis in Africa).

Connect with a study center

  • Infectious Diseases Institute, Makerere University

    Kampala,
    Uganda

    Active - Recruiting

  • Kiruddu National Referral Hospital

    Kampala,
    Uganda

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.